Literature DB >> 20298763

MDMA causes a redistribution of serotonin transporter from the cell surface to the intracellular compartment by a mechanism independent of phospho-p38-mitogen activated protein kinase activation.

B Kivell1, D Day, P Bosch, S Schenk, J Miller.   

Abstract

3,4-methylenedioxymethamphetamine (MDMA) causes long-term serotonin depletion and reduced serotonin transporter (SERT) function in humans and in animal models. Using quantitative Western blotting and real-time PCR, we have shown that total SERT protein in the striatum and nucleus accumbens and mRNA levels in the dorsal raphe nucleus were not significantly changed following MDMA exposure in rats (4 x 2 h i.p. injections, 10 mg/kg each). In mouse neuroblastoma (N(2)A) cells transiently expressing green fluorescent protein-tagged human SERT (GFP-hSERT), we have shown redistribution of SERT from the cell surface to intracellular vesicles on exposure to MDMA using cell surface biotinylation, total internal reflection fluorescence microscopy (TIRFM) and live-cell confocal microscopy. To investigate the mechanism responsible for SERT redistribution, we used specific antibodies to phospho-p38-mitogen activated protein kinase (p38 MAPK), a known signalling pathway involved in SERT membrane expression. We found that p38 MAPK activation was not involved in the MDMA-induced redistribution of SERT from the cell-surface to the cell interior. A loss of SERT from the cell surface on acute exposure to MDMA may contribute to the decreased SERT function seen in rats exposed to MDMA. 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20298763     DOI: 10.1016/j.neuroscience.2010.03.018

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Ultrastructural characterization of tryptophan hydroxylase 2-specific cortical serotonergic fibers and dorsal raphe neuronal cell bodies after MDMA treatment in rat.

Authors:  Csaba Adori; Péter Low; Rómeó D Andó; Lise Gutknecht; Dorottya Pap; Ferencné Truszka; József Takács; Gábor G Kovács; Klaus-Peter Lesch; György Bagdy
Journal:  Psychopharmacology (Berl)       Date:  2010-10-30       Impact factor: 4.530

Review 2.  The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Authors:  Yosta Vegting; Liesbeth Reneman; Jan Booij
Journal:  Psychopharmacology (Berl)       Date:  2016-08-28       Impact factor: 4.530

3.  Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake.

Authors:  Samanta Yubero-Lahoz; K P C Kuypers; J G Ramaekers; Klaus Langohr; Magí Farré; Rafael de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2014-12-20       Impact factor: 4.530

4.  Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys.

Authors:  Robert W Gould; H Donald Gage; Matthew L Banks; Brandi L Blaylock; Paul W Czoty; Michael A Nader
Journal:  Neuropharmacology       Date:  2011-04-17       Impact factor: 5.250

5.  Effect of repeated exposure to MDMA on the function of the 5-HT transporter as assessed by synaptosomal 5-HT uptake.

Authors:  Courtney Huff; Nirmal Bhide; Allen Schroering; Bryan K Yamamoto; Gary A Gudelsky
Journal:  Brain Res Bull       Date:  2013-01-12       Impact factor: 4.077

6.  Neonatal citalopram treatment inhibits the 5-HT depleting effects of MDMA exposure in rats.

Authors:  Tori L Schaefer; Curtis E Grace; Matthew R Skelton; Devon L Graham; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  ACS Chem Neurosci       Date:  2011-10-21       Impact factor: 4.418

7.  Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.

Authors:  B Simonson; A S Morani; A W M Ewald; L Walker; N Kumar; D Simpson; J H Miller; T E Prisinzano; B M Kivell
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.